Mark Killion

Mark Killion has a diverse work experience spanning over several decades. Mark began their career as a Territory Sales Representative at Mylan Bertek Pharmaceuticals in 1994. Mark later worked as an Area Business Manager/Regional Business Manager at Savient Pharmaceuticals, where they achieved significant sales growth.

In 2004, Mark joined Acorda Therapeutics as an Area Director, and in 2009, they became a Regional Business Director at Actavis.

Mark's career continued to progress, and they joined Pearl Pathways in 2013 as a Business Development Director. Mark worked with Pearl Pathways to expedite life science product development regulatory pathways.

Mark gained experience in the branded pharmaceutical sales division as the West Area Director of Sales at Perrigo Company plc. Mark managed the sales organization and oversaw all training activities for three Women's Health Products and Bacitracin ophthalmic ointment.

From 2017 to 2020, Mark worked at UCB, first as a Senior District Sales Manager and then as an Immunology Ecosystem Partnership Lead. In these roles, they promoted Cimzia and delivered the immunology value proposition to various stakeholders.

Mark's most recent positions include being the West Region RBD at Chiasma and the Regional Business Director at Amryt Pharma plc. In these roles, they led teams, developed regional strategies, and executed tactical plans for the treatment of acromegaly in the rare disease space.

Currently, Mark is working as a Regional Sales Director at Chiesi USA, Inc., where they are responsible for leading sales efforts in a specific region.

Overall, Mark Killion has extensive experience in sales and leadership roles within the pharmaceutical industry, with a focus on rare disease treatments.

Mark Killion attended Indiana University Bloomington from 1985 to 1989. Mark obtained a Bachelor of Arts (B.A.) degree during this time, but the specific field of study is not known.